To investigate treatment-specific mutations that underlie resistance to treatment with chemotherapy +/- bevacizumab or cetuximab in 1L mCRC, we performed targeted sequencing of circulating free DNA (cfDNA) from longitudinal plasma samples collected at baseline (PRE, n=354), during treatment (OTH, n=254), and/or at progression or end of the protocol treatment (EOT, n=345). This dataset contains the resulting BAM files.: Sample A8515501
plasma cfDNA is extracted, repaired, tagged with nonrandom oligonucleotide barcodes and enriched by  hybrid capture